First AD

Second AD

Tanya B. Dorff, MD, is section chief of the Genitourinary Disease Program and professor in the Department of Medical Oncology and Therapeutics Research at City of Hope in Duarte, California. 

Data from the DEAR Real-World Study and Strategies for Optimizing Outcomes 

Prostate Cancer

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

OncLive News Network®

® video programs provide lively discussions, insights, and expert perspectives on important issues facing today’s cancer care professionals. One variation of the program, titled, 

, comprises live virtual or on-site premium reporting for oncologists as it covers the latest news and information coming out of the largest annual oncology conferences. 

Optimizing Care Across the Continuum: Updates in the Detection and Treatment of Prostate Cancer

Drs. Dorff and McKay discuss real-world data from DEAR trial comparing darolutamide, enzalutamide and apalutamide, providing clinical pearls on their experiences to optimize outcomes.